ArticleThe oncologist2025

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation.

Fabian Kleinhenz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.